Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Royer

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Blood|December 14, 2023
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case seriesNathalie Forgeard, Dikélélé Elessa, Alexander Carpinteiro, et al.
Blood|February 29, 2020
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosisMurielle Roussel, Giampaolo Merlini, Sylvie Chevret, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2025
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) CohortCyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, et al.
The American Journal of Medicine|December 4, 2012
Bone complications of mastocytosis: a link between clinical and biological characteristicsNicolas Guillaume, Judith Desoutter, Olivia Chandesris, et al.
American Journal of Hematology|August 10, 2019
Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case seriesJean-Simon Rech, Bertrand Arnulf, Constance de Margerie-Mellon, et al.
Haematologica|August 16, 2023
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life studyPierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, et al.
Haematologica|March 17, 2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemiaPierre Feugier, Thérèse Aurran, Béatrice Mahé, et al.
The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trialMurielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphomaVéronique Leblond, Steve Johnson, Sylvie Chevret, et al.
Blood|June 30, 2016
Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopeniaMatthieu Mahévas, Mathieu Gerfaud-Valentin, Guillaume Moulis, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Blood|December 14, 2023
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case seriesNathalie Forgeard, Dikélélé Elessa, Alexander Carpinteiro, et al.
Blood|February 29, 2020
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosisMurielle Roussel, Giampaolo Merlini, Sylvie Chevret, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2025
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) CohortCyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, et al.
The American Journal of Medicine|December 4, 2012
Bone complications of mastocytosis: a link between clinical and biological characteristicsNicolas Guillaume, Judith Desoutter, Olivia Chandesris, et al.
American Journal of Hematology|August 10, 2019
Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case seriesJean-Simon Rech, Bertrand Arnulf, Constance de Margerie-Mellon, et al.
Haematologica|August 16, 2023
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life studyPierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, et al.
Haematologica|March 17, 2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemiaPierre Feugier, Thérèse Aurran, Béatrice Mahé, et al.
The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trialMurielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphomaVéronique Leblond, Steve Johnson, Sylvie Chevret, et al.
Blood|June 30, 2016
Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopeniaMatthieu Mahévas, Mathieu Gerfaud-Valentin, Guillaume Moulis, et al.
Pageof 11